What biomarkers should I test for SIBO (Small Intestinal Bacterial Overgrowth)?

The primary biomarkers to test for SIBO (Small Intestinal Bacterial Overgrowth) include: Lactulose Breath Test, Hydrogen Predominance, Methane Predominance, Dysbiosis Markers. Testing lactose or glucose breath test detects SIBO. If positive, rifaxomicin plus diet modification typically resolves SIBO within 2-4 weeks.

How can biomarker testing help with SIBO (Small Intestinal Bacterial Overgrowth)?

Standard gastroenterology does not test for SIBO. But breath testing can detect it, and antimicrobial therapy resolves it in most cases. Testing lactose or glucose breath test detects SIBO. If positive, rifaxomicin plus diet modification typically resolves SIBO within 2-4 weeks.

What is Lactulose Breath Test and how does it relate to SIBO (Small Intestinal Bacterial Overgrowth)?

Lactulose is not absorbed in small intestine. If bacteria are present, they ferment lactulose, producing hydrogen/methane. Breath test measures these gases. Target range: Negative: no increase in H2/CH4. If positive (>20 ppm increase within 90 minutes), rifaxomicin 200 mg TID x 14 days is first-line antimicrobial therapy. Retest 4 weeks after treatment.

What is Hydrogen Predominance and how does it relate to SIBO (Small Intestinal Bacterial Overgrowth)?

Most SIBO (80%) is hydrogen-predominant. Responds well to rifaxomicin and dietary restriction of fermentable carbs. Target range: < 20 ppm baseline; peak < 90 min. Hydrogen-predominant SIBO responds well to standard antimicrobial therapy. Retest 4 weeks after treatment to confirm clearance.

What is Methane Predominance and how does it relate to SIBO (Small Intestinal Bacterial Overgrowth)?

Methane SIBO (20% of cases) is methane-producing archaea. Associated with constipation. Requires specific antimicrobial choices. Target range: < 12 ppm baseline; peak < 90 min. Methane SIBO may need combination therapy (rifaxomicin + neomycin) or alternative agents. Neomycin targets methane producers. Retest after treatment.

SIBO Biomarkers - SIBO is bacterial overgrowth in the small intestine causing bloating, gas, and nutrient malabsorption. Testing and antimicrobial therapy resolve SIBO.

SIBO Biomarkers: SIBO is bacterial overgrowth in the small intestine causing bloating, gas, and nutrient malabsorption. Testing and antimicrobial therapy resolve SIBO.

SIBO is present in 60-80% of IBS patients and is highly treatable. But it is rarely diagnosed due to limited testing availability.

Category: Digestive Health

The Issue

Standard gastroenterology does not test for SIBO. But breath testing can detect it, and antimicrobial therapy resolves it in most cases.

The Action

Testing lactose or glucose breath test detects SIBO. If positive, rifaxomicin plus diet modification typically resolves SIBO within 2-4 weeks.

Primary Causes & Action Plans

Lactulose Breath Test

Gold-standard test for SIBO

Lactulose is not absorbed in small intestine. If bacteria are present, they ferment lactulose, producing hydrogen/methane. Breath test measures these gases.

Target Negative: no increase in H2/CH4

Suggested Action Plan

If positive (>20 ppm increase within 90 minutes), rifaxomicin 200 mg TID x 14 days is first-line antimicrobial therapy. Retest 4 weeks after treatment.

Hydrogen Predominance

Hydrogen-predominant SIBO (most common type)

Most SIBO (80%) is hydrogen-predominant. Responds well to rifaxomicin and dietary restriction of fermentable carbs.

Target < 20 ppm baseline; peak < 90 min

Suggested Action Plan

Hydrogen-predominant SIBO responds well to standard antimicrobial therapy. Retest 4 weeks after treatment to confirm clearance.

Methane Predominance

Methane-predominant SIBO (associated with constipation)

Methane SIBO (20% of cases) is methane-producing archaea. Associated with constipation. Requires specific antimicrobial choices.

Target < 12 ppm baseline; peak < 90 min

Suggested Action Plan

Methane SIBO may need combination therapy (rifaxomicin + neomycin) or alternative agents. Neomycin targets methane producers. Retest after treatment.

Dysbiosis Markers

Microbial imbalance contributing to SIBO

Dysbiosis (low beneficial bacteria, high pathogenic) contributes to SIBO. Microbiome testing can identify dysbiosis patterns.

Target Healthy diversity

Suggested Action Plan

After antimicrobial therapy, restore dysbiosis with probiotics and prebiotic fiber. Some benefit from continued elemental diet.

SIBO Biomarkers: SIBO is bacterial overgrowth in the small intestine causing bloating, gas, and nutrient malabsorption. Testing and antimicrobial therapy resolve SIBO.

The Issue

The Action

Primary Causes & Action Plans

Lactulose Breath Test

Suggested Action Plan

Hydrogen Predominance

Suggested Action Plan

Methane Predominance

Suggested Action Plan

Dysbiosis Markers

Suggested Action Plan

Also in Digestive Health

Explore by Biomarker

Getting Started

Test for SIBO via Breath Test

Start Antimicrobial Therapy

Adopt Low-FODMAP Diet Temporarily

Restore Healthy Microbiome

Retest 4 Weeks Post-Treatment

Why I built this guide.

Explore More

Get a Discount

Read Our Review

Is It Worth It?

Compare All Insurers

Cure Your SIBO